The Company

Company History

Hepyx is built on the work of Prof. Rajiv Jalan, its lead scientific founder, and his colleagues at UCL. The translational pathway builds on work at the UCL Royal Free Hospital campus as well through collaborations with peers in Europe, the Americas and Asia.

The Company was incorporated in 2019. At the core of its clinical development work has been its memberships of consortium focused on the development of the HPX-001 candidate. This consortium was formed to apply for grants under the European Horizon 2020 scheme and consist primarily of clinical trial research hospital sites in Europe. Consortium members specialise in clinical trials management, data analysis and dissemination of trial outputs. The consortium was awarded a grant value of €6 million in non-dilutive funding to execute a randomised controlled trial for HPX-001. The other pipeline products are also continuing various stages of research and development.